Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.
Ophthalmol Sci
; 2(1): 100095, 2022 Mar.
Article
en En
| MEDLINE
| ID: mdl-36246187
AE, adverse event; AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; DC, drusen complex; Dry age-related macular degeneration; Elamipretide; FAF, fundus autofluorescence; GA, geographic atrophy; HRD, high-risk drusen; LLQ, low-luminance questionnaire; LLRA, low-luminance binocular reading acuity; LLVA, low-luminance best-corrected visual acuity; Mitochondrial dysfunction; NCGA, noncentral, fovea-sparing geographic atrophy; NLRA, normal-luminance binocular reading acuity; Phase 1 clinical trial; RPE, retinal pigment epithelium; Retina; SD, standard deviation; logMAR, logarithm of the minimum angle of resolution
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Ophthalmol Sci
Año:
2022
Tipo del documento:
Article